Cantargia AB CANTA
OMXSTO · Sweden · Health Technology
SEK 1.46-0.01 (-0.41%)
Market open· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
LUND, SE / ACCESS Newswire / September 30, 2026 / AB (publ) (STO:CANTA) today announced the presentation of a poster on nadunolimab in combination with RAS inhibition in pancreatic ductal adenocarcinoma (PDAC) at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development. The preclinical data were generated in a research study at Fred Hutch Cancer Center.
LUND, SE / ACCESS Newswire / August 28, 2026 / AB (publ) (Nasdaq Stockholm:CANTA) today announced that management will participate in the following investor conferences during September 2026. Wainwright - 28th Annual Global Investment Conference 2026, New York * Company Presentation by Hilde Steineger, CEO * Investor meetings * September 14 at 10.
Company reports complete remission in all evaluable high-risk MDS patients and secures funding to extend runway into mid-2028.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.